Cephalon Names Vice President of Risk Management


	Advertise with Sarbanes Oxley Compliance Journal

News

< Back

Sarbanes Oxley : People

Cephalon Names Vice President of Risk Management

Cephalon, announced the appointment of Stephen Burns to Vice President, Risk Management.

Stephen Burns

Celphalon

Stephen J. Burns joined Cephalon as Vice President, Risk Management with responsibility for guiding a holistic approach to Cephalon's management of risk, including establishing a company-wide internal audit program and directing corporate insurance activities. Initially his efforts will be focused on ensuring compliance with Sarbanes-Oxley section 404 requirements.

Previously, Burns served as Director, Business Analysis and Acting Finance Director - North America, for MDS International's Clinical Research Organization business. He also has held management consulting roles with SAP and PricewaterhouseCoopers, advising pharmaceutical clients including GlaxoSmithKline (GSK) and Bayer.

A long-time resident of Europe, Burns was Internal Audit Director for one of France's largest manufacturing companies, where he was responsible for internal control and operations analysis for industrial sites in more than thirty countries on four continents. He began his business career in 1979 as a financial analyst with Exxon Corporation.

"With the increasing complexity of our operations, it's essential that Cephalon have an effective risk management program in place," said J. Kevin Buchi, Senior Vice President and Chief Financial Officer. "Stephen's expertise in developing internal control and risk mitigation strategies on a worldwide basis will help us manage our business more effectively."

Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products to treat sleep and neurological disorders, cancer and pain.

Cephalon currently employs approximately 2,000 people in the United States and Europe. U.S. sites include the company's headquarters in West Chester, Pennsylvania, and offices and manufacturing facilities in Salt Lake City, Utah. Cephalon's major European offices are located in Guildford, England, Martinsried, Germany, and Maisons-Alfort, France.

The company currently markets three proprietary products in the United States: PROVIGIL? (modafinil) Tablets [C-IV], GABITRIL? (tiagabine hydrochloride) and ACTIQ? (oral transmucosal fentanyl citrate) [C-II] and more than 20 products internationally.

About Us

Editorial